These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

221 related items for PubMed ID: 10397375

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Safety profile of sparfloxacin in the treatment of respiratory tract infections.
    Rubinstein E.
    J Antimicrob Chemother; 1996 May; 37 Suppl A():145-60. PubMed ID: 8737134
    [Abstract] [Full Text] [Related]

  • 25. Moxifloxacin: a review of its clinical potential in the management of community-acquired respiratory tract infections.
    Balfour JA, Lamb HM.
    Drugs; 2000 Jan; 59(1):115-39. PubMed ID: 10718103
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Antimicrobial activity of a novel peptide deformylase inhibitor, LBM415, tested against respiratory tract and cutaneous infection pathogens: a global surveillance report (2003-2004).
    Watters AA, Jones RN, Leeds JA, Denys G, Sader HS, Fritsche TR.
    J Antimicrob Chemother; 2006 May; 57(5):914-23. PubMed ID: 16549511
    [Abstract] [Full Text] [Related]

  • 32. Multicenter evaluation of the efficacy and safety of gatifloxacin in Mexican adult outpatients with respiratory tract infections.
    Casillas JL, Rico G, Rodríguez-Parga D, Mascareño A, Rangel-Frausto S.
    Adv Ther; 2000 May; 17(6):263-71. PubMed ID: 11317829
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. [Antimicrobial susceptibility of community-acquired respiratory tract pathogens isolated from adults in China during 2009 and 2010].
    Wang H, Liu YL, Chen MJ, Xu YC, Sun HL, Yang QW, Hu YJ, Cao B, Chu YZ, Liu Y, Zhang R, Yu YS, Sun ZY, Zhuo C, Ni YX, Hu BJ.
    Zhonghua Jie He He Hu Xi Za Zhi; 2012 Feb; 35(2):113-9. PubMed ID: 22455967
    [Abstract] [Full Text] [Related]

  • 35. [Cefditoren and community-acquired lower respiratory tract infections (corrected)].
    Barberán J, Mensa J.
    Rev Esp Quimioter; 2009 Sep; 22(3):144-50. PubMed ID: 19662548
    [Abstract] [Full Text] [Related]

  • 36. Telithromycin: a new ketolide antimicrobial for treatment of respiratory tract infections.
    Yassin HM, Dever LL.
    Expert Opin Investig Drugs; 2001 Feb; 10(2):353-67. PubMed ID: 11178347
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Comparative in vitro activity of older and newer fluoroquinolones against respiratory tract pathogens.
    Esposito S, Noviello S, Ianniello F.
    Chemotherapy; 2000 Feb; 46(5):309-14. PubMed ID: 10965095
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.